Spire Healthcare Group (LON:SPI) Stock Price Down 18.1% on Analyst Downgrade

Shares of Spire Healthcare Group plc (LON:SPI) were down 18.1% during trading on Thursday after Deutsche Bank Aktiengesellschaft lowered their price target on the stock from GBX 320 to GBX 300. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock. Spire Healthcare Group traded as low as GBX 169 ($2.18) and last traded at GBX 183.95 ($2.38). Approximately 8,024,729 shares were traded during trading, an increase of 1,005% from the average daily volume of 726,218 shares. The stock had previously closed at GBX 224.50 ($2.90).

Spire Healthcare Group Price Performance

The company has a market cap of £711.58 million, a PE ratio of 25.22, a PEG ratio of 1.06 and a beta of 0.96. The company has a debt-to-equity ratio of 62.25, a current ratio of 0.70 and a quick ratio of 0.74. The stock’s 50-day moving average is GBX 227.28 and its 200 day moving average is GBX 229.74.

Spire Healthcare Group (LON:SPI) last issued its quarterly earnings data on Thursday, March 6th. The company reported GBX 8.80 ($0.11) EPS for the quarter. Spire Healthcare Group had a return on equity of 3.82% and a net margin of 1.96%. On average, equities analysts anticipate that Spire Healthcare Group plc will post 15.6634747 earnings per share for the current fiscal year.

About Spire Healthcare Group

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.